L3VLUP
ProSign in

NTRA · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NTRAJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NTRA
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterNTRAJNJ
Q3 202016 holders, $575m30 holders, $26.2bn
Q4 202015 holders, $741m32 holders, $26.6bn
Q1 202117 holders, $911m31 holders, $25.3bn
Q2 202120 holders, $1.4bn37 holders, $25.6bn
Q3 202117 holders, $1.3bn40 holders, $24.1bn
Q4 202114 holders, $1.2bn33 holders, $25.2bn
Q1 202213 holders, $551m35 holders, $28.2bn
Q2 202214 holders, $473m33 holders, $26.9bn
Q3 202210 holders, $365m36 holders, $25.4bn
Q4 202212 holders, $266m35 holders, $27.6bn
Q1 202314 holders, $658m42 holders, $24.5bn
Q2 202310 holders, $474m38 holders, $25.0bn
Q3 202310 holders, $554m37 holders, $18.9bn
Q4 202312 holders, $695m31 holders, $19.0bn
Q1 202418 holders, $2.0bn32 holders, $19.7bn
Q2 202422 holders, $2.5bn35 holders, $20.4bn
Q3 202425 holders, $3.6bn28 holders, $22.3bn
Q4 202428 holders, $4.5bn37 holders, $20.4bn
Q1 202521 holders, $4.6bn32 holders, $20.5bn
Q2 202521 holders, $5.4bn31 holders, $18.4bn
Q3 202523 holders, $4.8bn32 holders, $23.7bn
Q4 202526 holders, $8.1bn29 holders, $27.8bn
Q1 202620 holders, $6.7bn34 holders, $35.6bn
Q2 202623 holders, $10.0bn33 holders, $39.1bn
NTRA

Natera Inc

Holders
23
Reported value
$4.8bn
Buyers
11
Sellers
11

Breadth 0 among 95 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
32
Reported value
$23.7bn
Buyers
17
Sellers
13

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NTRA (13)

ARK Investment Management LLC, Artisan Partners LP, Capital World Investors, Coatue Management LLC, Farallon Capital Management LLC, Holocene Advisors LP, Maverick Capital Ltd, PDT Partners LLC, Point72 Asset Management LP, Polen Capital Management LLC, Rokos Capital Management LLP, Verition Fund Management LLC, Winton Group Ltd

Only JNJ (22)

Acadian Asset Management LLC, AllianceBernstein LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Squarepoint Ops LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →